舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状的疗效及安全性分析

张玉波; 孙燕; 李佳桂; 祖庆余; 赵静; 张彬辉; 刘红静; 陈立敏

doi:10.3969/j.issn.1671-038X.2019.08.09

舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状的疗效及安全性分析

- 1. 涿州市医院消化内科, 河北涿州 072750;
- 2. 涿州市医院重症医学科, 河北涿州 072750
基金项目:
保定市科技计划项目(No:17ZF118)

详细信息

作者简介:
张玉波,男,硕士,副主任医师,研究方向:胃肠胆胰病学、肝脏病学以及消化内镜诊疗

通讯作者: 李佳桂,E-mail:qaz301214@126.com

中图分类号: R575

收稿日期: 2019-03-02

The efficacy and safety analysis of Shugan Jieyu capsule combined with clomipramine in the treatment of liver disease related somatic symptoms

- 1. Department of Gastroenterology, Zhuozhou Hospital, Hebei Province, Zhuozhou 072750, China;
- 2. Department of Critical Care Medicine, Zhuozhou Hospital, Hebei Province, Zhuozhou 072750, China

More Information

Corresponding author: LI Jia-gui, E-mail: qaz301214@126.com

Received Date: 02 March 2019

摘要

摘要: [目的]研究舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状的疗效及安全性分析。[方法]选取我院收治的肝病相关躯体化症状患者90例,随机分为2组,每组各45例。对照组患者口服盐酸氯米帕明片,1片/次,2次/d,治疗组在对照组基础上每日给予舒肝解郁胶囊,2粒/次,2次/d,早晚各1次,2组患者持续治疗6周。对比2组临床疗效、HAMD评分、HAMA评分和TESS评分。[结果]经过治疗后,2组治疗有效率进行比较,治疗组较高(P＜0.05);2组患者HAMD评分和HAMA评分均显著低于治疗前(P＜0.05);并且治疗组降低程度较大(P＜0.05);2组患者TESS评分差异无统计学意义。[结论]采用舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状,具有较好的临床疗效,能够改善患者HAMD评分和HAMA评分,安全性较高,值得在临床推广应用。
- 舒肝解郁胶囊 /
- 氯米帕明 /
- 肝病相关躯体化症状 /
- 安全性分析
Abstract: [Objective]To investigate the efficacy and safety of shugan jieyu capsule combined with clomiphene in the treatment of liver disease-related somatic symptoms.[Methods]90 patients with liver disease-related somatic symptoms admitted to our hospital were randomly divided into two groups of 45 patients each.Patients in the control group were given clomipramine hydrochloride tablets orally,1 tablet per time and 2 times per day.On the basis of the control group,patients in the treatment group were given shugan jieyu capsules every day,2 tablets per time and 2 times per day,once in the morning and once in the evening.Patients in the two groups received continuous treatment for 6 weeks.Clinical efficacy,HAMD score,HAMA score and TESS score were compared between the two groups.[Results]After treatment,the effective rates of the two groups were compared,and were higher in the treatment group(P＜0.05).HAMD score and HAMA score were significantly lower in the two groups than before treatment(P＜0.05).In addition,the degree of reduction was greater in the treatment group(P＜0.05).There was no significant difference in TESS score between treatment group and control group(P＞0.05).[Conclusion]Shugan jieyu capsule combined with clomiphene for the treatment of liver disease-related somatic symptoms has a good clinical effect,which can improve the patient's HAMD score and HAMA score,and has high safety.It is worthy of clinical application.
- Shugan Jieyu capsule /
- clomipramine /
- liver disease related somatic symptoms /
- safety analysis

HTML全文

参考文献(15)

[1]	黄宗声, 郭先文, 左国文, 等.肠易激综合征患者肠外躯体化症状与焦虑相关性分析[J].临床消化病杂志, 2017, 22 (2):180-182.
[2]	明文, 向军英, 李群华, 等.功能性消化不良患者躯体化与焦虑相关性的研究[J].川北医学院学报, 2016, 31 (2):125-128.
[3]	王云琼, 何影.帕罗西汀片和氯米帕明片治疗抑郁症的临床研究[J].中国临床药理学杂志, 2017, 5 (15):121-123.
[4]	陈科.舒肝解郁胶囊联合舍曲林改善老年精神分裂症阴性症状的效果研究[J].中华全科医学, 2016, 14 (5):780-781.
[5]	曹森林.加味三香汤联合复方消化酶治疗对肝郁脾虚型功能性消化不良患者疗效及焦虑抑郁状态的影响[J].中国中西医结合消化杂志, 2018, 26 (1):83-86..
[6]	于迎, 庄红艳, 尹冬青, 等.中医体质类型与抗精神病药物不良反应的关系研究[J].首都医科大学学报, 2018, 4 (2):204-208.
[7]	单海燕, 张雪莹, 谷海燕, 等.电针联合五音疗法治疗伴焦虑抑郁状态溃疡性结肠炎40例临床观察[J].中国中西医结合消化杂志, 2018, 26 (9):66-68, 73.
[8]	杜明君, 肖伟霞, 申丽娟, 等.西酞普兰联合中药郁乐方治疗对于抑郁症的HAMD、HAMA、MADS评分及安全性研究[J].国际精神病学杂志, 2018, 6 (1):17-20.
[9]	刘伟, 王静, 王钦鹏, 等.乌灵胶囊联合盐酸文拉法辛缓释胶囊治疗脑梗死后患者躯体化症状的评价[J].中国现代医学杂志, 2018, 28 (24):62-65.
[10]	汪谋岳, 中华医学会神经病学分会神经心理学与行为神经病学组.综合医院焦虑、抑郁与躯体化症状诊断治疗的专家共识[J].中华神经科杂志, 2016, 49 (12):908.
[11]	陈文泽, 陈雪芬, 张君青, 等.躯体化障碍者的治疗及其神经电生理指标的变化研究[J].浙江医学, 2016, 38 (10):688-690.
[12]	中华医学会神经病学分会神经心理学与行为神经病学组.综合医院焦虑、抑郁与躯体化症状诊断治疗的专家共识[J].中华神经科杂志, 2016, 49 (12):95-98.
[13]	马闯胜, 马玲, 张淑芳, 等.氯米帕明治疗难治性抑郁症对照研究[J].临床精神医学杂志, 2016, 26 (4):274-274.
[14]	李前龙, 古赛.舒肝解郁胶囊治疗伴轻中度抑郁症的功能性消化不良的临床效果观察[J].临床消化病杂志, 2016, 28 (1):13-16.
[15]	任虹, 孙俊伟.疏肝解郁胶囊联合文拉法辛治疗伴有躯体症状老年抑郁症对照研究[J].中国药物与临床, 2016, 16 (1):77-79.